Former Twitter Namaste Howard Marks Rule your Mind or it will Rule you

CNN: Full approval of the Pfizer-BioNTech#COVID19 vaccine opens the door for more vaccination-only mandates throughout the U.S.

@disclosetv

Patriot, Conservative, Prayer Warrior, PureBlood! ...Love & Gratitude ... Kind heart, fierce mind, brave spirit !

In response Dennis 369 to his Publication

I heard it was NOT approved - only the Emergency Use Auth. was extended - is the media LYING ... again???

Independent Patriot*@PeacockStarry on Twitter*also on Gab*Reiki Master*Starbeing*Vegetarian*#SaveOurChildren #Arkansas #greatawakening

In response Dennis 1776 to his Publication

This was a screenshot posted from fda.gov
Yes the media are lying dogs - again

Patriot, Conservative, Prayer Warrior, PureBlood! ...Love & Gratitude ... Kind heart, fierce mind, brave spirit !

In response Starry Peacock to her Publication

TY for confirming !!! YES !!!

In response Dennis 1776 to his Publication

read the first paragraph
Today, the U.S. Food and Drug Administration approved the first COVID-19 vaccine. The vaccine has been known as the Pfizer-BioNTech COVID-19 Vaccine, and will now be marketed as Comirnaty (koe-mir’-na-tee), for the prevention of COVID-19 disease in individuals 16 years of age and older. The vaccine also continues to be available under emergency use authorization (EUA), including for individuals 12 through 15 years of age and for the administration of a third dose in certain immunocompromised individuals.

The ‘data’ or ‘study’ that the FDA references in the website to aid in FDA approval decision is looking at 20k people
receiving the second dose and 20k receiving a placebo. and monitoring whether or not they get covid 19 symptoms. a large amount did not get symptoms
therefore the conclusion is the vax is effective at preventing serious outcomes & hospitalizations.
🤣🤣🤣🤣🤣🤣🤣

In response Leslie Henson to her Publication

Only people mentioned by @Kellymalinoski in this post can reply

No replys yet!

It seems that this publication does not yet have any comments. In order to respond to this publication from Kelly Malinoski, click on at the bottom under it